A Prospective Randomised Multicentre Phase III Clinical Trial Comparing the Effects of Panorex Injection Plus 5-Fluorouracil (5-FU)/Leucovorin versus 5-Fluorouracil/Leucovorin versus PANOREX alone, in patients with Surgically resected Stage III (Dukes C) Carcinoma of the Colo
Phase 3
Completed
- Conditions
- CancerColonColon cancer
- Registration Number
- ISRCTN18439984
- Lead Sponsor
- Glaxo Wellcome (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Histopathologically documented stage III (Dukes C) colon cancer
2. Less than 6 weeks since surgical removal of the tumour
3. Tumour-free margin of resection
4. Total resection of tumour by laparoscopy is an exclusion
5. Age >18: World Health Organisation (WHO) performance status of 0, 1 or 2: Life expectancy at least 12 months
6. Adequate haematological, hepatic and renal function
7. No metastatic, recurrent, locally advanced cancer or previous history of cancer
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot provided at time of registration
- Secondary Outcome Measures
Name Time Method ot provided at time of registration